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Introduction
Atrial fibrillation (AF) is the most common sus-
tained arrhythmia in elderly adults and its prevalence 
increases with age [1, 2]. One of the most impor-
tant complications associated with AF is ischemic 
strokes, and AF-related stroke is more likely to 
result in disability, dementia, and death [3]. While 
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Abstract
Background: Elderly adults with atrial fibrillation (AF) are at increased risk of frailty and thromboembolic complica-
tions. However, studies on the prevalence of frailty in AF patients and data on the relationship between frailty and the 
use of anticoagulants are limited.
Methods: We conducted a cross-sectional study involving 500 participants. Patients aged 65 years or older were con-
secutively selected from the Chinese Atrial Fibrillation Registry study. The patient’s frailty status was assessed with use 
of the Canadian Study of Health and Aging Clinical Frailty Scale. We assessed the prevalence of and factors associated 
with frailty, and how frailty affects anticoagulant therapy.
Results: In 500 elderly adults with AF (age 75.2 ± 6.7 years; 51.6% female), 201 patients (40.2%) were frail. The 
prevalence of frailty was higher in females (P = 0.002) and increased with age and CHA
2
DS
2
-VASc score (P for trend 
less than 0.001 for both). The factors associated with frailty were a history of heart failure (odds ratio [OR] 2.40, 95% 
confidence interval [CI] 1.39–4.14), female sex (OR 2.09, 95% CI 1.27–3.43), and advanced age (OR 1.13, 95% CI 
1.09–1.17). Frail patients were significantly less likely to have ever been prescribed anticoagulants compared with 
nonfrail patients (81.7 vs. 54.9%, P < 0.001).
Conclusions: Frailty is prevalent in elderly adults with AF, especially in females, those of advanced age, and those 
with heart failure. Frailty status has a significant impact on prescription of anticoagulants for high-risk AF patients.
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oral anticoagulants (OACs) significantly reduce the 
risk of stroke, challenges remain in appropriate risk 
assessment, treatment adherence, and guideline-
adherent prescribing [4, 5]. Of note, up to half of 
elderly adults with AF do not receive anticoagu-
lant therapy because of its perceived side effects, 
but such nonprescribing leads to more adverse out-
comes [6–8].
Frailty is defined as a state of vulnerability to 
adverse outcomes from stressors [9]. The preva-
lence and clinical significance of frailty increase 
with aging [10, 11]. Frailty is a strong independent 
predictor of cardiovascular-related death and is also 
associated with pathophysiological factors in the 
development of cardiovascular diseases and throm-
bosis [12]. The prevalence of frailty in elderly adults 
with cardiovascular diseases is reported to be three 
times higher than in those without cardiovascular 
diseases [13]. However, data on the prevalence of 
frailty in elderly adults with AF are limited, espe-
cially from Asian countries. Moreover, the find-
ings of studies on the prevalence of anticoagulant 
prescription according to frailty status are not con-
sistent [14]. The present study aimed to investigate 
the prevalence of frailty in elderly adults with AF, 
factors associated with frailty status, and the preva-
lence of OAC therapy in frail and nonfrail patients 
in this population.
Methods
Study Population
We consecutively selected 500 nonvalvular AF 
patients aged 65 years or older who were enrolled 
in the Chinese Atrial Fibrillation Registry (CAFR) 
study between April 2017 and December 2017. The 
CAFR study is a prospective, multicenter registry 
study that enrolled AF patients from hospital wards 
and outpatient clinics. All enrolled patients had AF 
documented by either ECG or Holter monitoring 
within the previous 6 months. Patients with tran-
sient and reversible AF, patients with diagnosed 
rheumatic heart disease, and patients who had 
undergone a left atrial appendage closure procedure 
were excluded from the present study. Data on the 
patients’ demographic characteristics, medical his-
tories, and treatments received were collected by 
face-to-face interview and medical record review 
at enrollment. Each patient was followed up by tel-
ephone every 6 months, and data on treatment and 
clinical outcomes were collected. All of the study 
patients were ambulatory when the current study 
was conducted. The CAFR study was reviewed 
and approved by the Ethics Committee of Beijing 
Anzhen Hospital. All patients signed consent forms. 
For the present study, we obtained separate ethics 
approval from the same hospital and obtained oral 
consent of the patients for the extra questions being 
asked.
Measurements
Measured factors included demographic charac-
teristics, chronic comorbidities, which includes: 
 congestive heart failure (CHF), hypertension, dia-
betes, coronary heart disease, hyperlipidemia, prior 
stroke/transient ischemic attack (TIA), vascular 
disease, major bleeding (International Society on 
Thrombosis and Haemostasis criteria: fatal bleed-
ing, and/or symptomatic bleeding in a critical area 
or organ, such as intracranial, intraspinal, intra-
ocular, retroperitoneal, intra-articular, or pericar-
dial, or intramuscular with compartment syndrome, 
and/or bleeding causing a fall in hemoglobin level 
of 2 g/dL or more or leading to transfusion of two or 
more units of whole blood or red cells [15]), chronic 
renal disease (dialysis, transplant, or creatinine level 
greater than 2.26 mg/dL), and chronic liver disease 
(cirrhosis or bilirubin level more than two times 
the upper normal limit with glutamic oxaloacetic 
transaminase/glutamic pyruvic transaminase/alka-
line phosphatase level more than three times the 
upper normal limit). The definitions of chronic 
renal disease and chronic liver disease are consist-
ent with the definitions used in the HAS-BLED 
scoring system. Data on other factors, including 
type of AF (paroxysmal or persistent), history of 
catheter ablation procedure(s), CHA2DS2-VASc 
score (1 point when a patient has a history of CHF, 
hypertension, diabetes mellitus, or vascular disease, 
is 65 years or older, or is female, and 2 points if a 
patient is 75 years or older or has a history of stroke/
TIA [16]), modified HAS-BLED score without 
labile international normalized ratio (1 point when 
a patient has a history of hypertension, abnormal 
renal/liver function, stroke, or bleeding tendency/
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predisposition, is elderly [>65 years old], and uses 
drugs/alcohol concomitantly [17]), the use of anti-
coagulants (warfarin and non-vitamin K antagonist 
OACs), and the number of concomitant medica-
tions (including antiarrhythmic drugs, rate control 
drugs, antiplatelet drugs, angiotensin-converting 
enzyme inhibitors or angiotensin receptor blockers, 
statins, and hypoglycemic agents) were also col-
lected. Then we evaluated the patient’s frailty status 
by telephone follow-up.
Frailty Status
The Canadian Study of Health and Aging Clinical 
Frailty Scale (CSHA-CFS) [18] was used to meas-
ure frailty. It assesses factors such as complications, 
cognitive function, and disability comprehensively 
(Supplementary Figure S1). The CSHA-CFS score 
has been widely used to evaluate frailty status world-
wide and to predict adverse outcomes such as death 
and hospitalization [19–22]. A recently published 
article reported that the CSHA-CFS has the highest 
sensitivity and specificity with the lowest misclassi-
fication rate among the screening tools for patients 
with heart failure [23]. A translated telephone ver-
sion of the CSHA-CFS [24] (Supplementary Figure 
S1) was administered by two trained investigators 
(LJP and LMM) through telephone interview. The 
instructions for use of the CSHA-CFS w strictly fol-
lowed when the interview was conducted and the 
CSHA-CFS score was assigned. The CSHA-CFS 
provides an estimation of frailty on a scale ranging 
from 1 to 7 based on the patient’s functional auton-
omy status, mobility, and need for assistance with 
activities of daily living. Patients were categorized 
into a nonfrail group (CSHA-CFS score less than 5) 
and a frail group (CSHA-CFS score 5 or greater) on 
the basis of their CSHA-CFS score.
Statistical Analysis
Demographic and clinical characteristics of the 
study population were summarized by descriptive 
analysis. Continuous variables are reported as the 
mean and the standard deviation or the median 
and the interquartile range and were compared by 
ANOVA. The categorical variables are expressed as 
a percentage and were compared by a chi-square test. 
We described the prevalence of frailty according to 
age, sex, and CHA2DS2-VASc score. Differences in 
the prevalence of frailty between male and female 
sex were tested by the chi-squared test; differences 
in the prevalence of frailty in different age groups 
and CHA
2
DS
2
-VASc score groups were tested by 
the Mantel-Haenszel test.
Multivariable logistic regression analysis was 
used to assess the factors associated with frailty 
status. Factors including age (as a continuous vari-
able), sex, previous or current smoking/alcohol 
drinking, history of CHF, hypertension, diabetes, 
coronary heart disease, hyperlipidemia, stroke/TIA, 
major bleeding, chronic liver disease, chronic renal 
disease, catheter ablation procedure, and type of 
AF were adjusted. The variables mentioned were 
selected to include all measured clinical variables 
of known or suspected factors for the frailty status.
Results
Of the 500 patients studied, 148 patients (29.6%), 
151 patients (30.2%), 92 patients (18.4%), 95 
patients (19.0%), and 14 patients (2.8%) were scored 
3, 4, 5, 6, and 7, respectively (Figure 1), and 201 
patients (40.2%) were categorized as frail (CSHA-
CFS score 5 or greater). Table 1 shows the baseline 
characteristics of patients in the frail and nonfrail 
groups. A higher proportion of frail patients were 
female (P = 0.002), had persistent AF (P = 0.009), 
and had CHF (P < 0.001). Frail patients were about 
5 years older than nonfrail patients (P < 0.001), had 
higher CHA
2
DS
2
-VASc scores (P < 0.001), and were 
taking more concomitant medications (P < 0.001), 
while they were less likely to have received catheter 
ablation (P = 0.026).
148
151
92
95
14 CSHA-CFS score
3
4
5
6
7
Figure 1 Distribution of Canadian Study of Health and 
Aging Clinical Frailty Scale (CSHA-CFS) Scores.
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Prevalence of Frailty in Patients Aged 
65 Years or Older with AF
The prevalence of frailty increased from 22.5% 
in the patients aged 65–69 years to 84.6% in the 
patients aged 85 years or older (Figure 2A; P for 
trend less than 0.001). A higher proportion of 
female patients (46.9%) were frail compared with 
male patients (33.1%; Figure 2B; P = 0.002). The 
proportion of the frail patients increased from 31.3 
to 59.7% as the CHA
2
DS
2
-VASc score increased 
from 1 to 6 or greater (Figure 2C; P for trend less 
than 0.001).
Factors Associated with Frailty
In multivariate logistic regression analysis, a his-
tory of CHF was the strongest factor associated 
with frailty (odds ratio [OR] 2.40, 95% confi-
dence interval [CI] 1.39–4.14, P = 0.002). Female 
sex (OR 2.09, 95% CI 1.27–3.43, P = 0.004) and 
advanced age (OR 1.13 for every year older, 95% 
Table 1 Demographic and Clinical Characteristics of the Study Population.
Characteristic  Overall 
(n = 500)
 Not frail (CSHA-
CFS score <5) 
(n = 299)
 Frail (CSHA-
CFS score ≥5) 
(n = 201)
 P-value
Age (years), mean (SD)  75.2 (6.7)  73.3 (5.9)  78.1 (6.7)  <0.001
Female, n (%)  258 (51.6)  137 (45.8)  121 (60.2)  0.002
CHF, n (%)  87 (17.4)  30 (10.0)  57 (28.4)  <0.001
Hypertension, n (%)  362 (72.4)  218 (72.9)  144 (71.6)  0.76
Diabetes, n (%)  140 (28.0)  80 (26.8)  60 (29.9)  0.45
Stroke/TIA, n (%)  99 (19.8)  53 (17.7)  46 (22.9)  0.16
Coronary artery disease, n (%)  148 (29.6)  86 (28.8)  62 (30.8)  0.62
Hyperlipidemia, n (%)  219 (43.8)  132 (44.1)  87 (43.3)  0.85
Major bleeding*, n (%)  27 (5.4)  12 (4.0)  15 (7.5)  0.09
Chronic liver disease, n (%)  109 (2)  3 (1)  4 (2)  0.05
Chronic kidney disease, n (%)  11 (2.2)  4 (1.3)  7 (3.5)  0.11
Previous or current smoking 
and drinking, n (%)
 151 (30.2)  95 (31.8)  56 (27.9)  0.35
Type of AF, n (%)
 Paroxysmal  232 (46.4)  153 (51.2)  79 (39.3)  0.009
 Persistent  268 (53.6)  146 (48.8)  122 (60.7)  
History of catheter ablation procedure, n (%)
 0  403 (80.6)  229 (76.6)  174 (86.6)  0.026
  ≥ 1  97 (19.4)  70 (23.4)  27 (13.4)  
CHA
2
DS
2
-VASc score, 
median (IQR)
 4 (3–5)  3 (2–4)  4 (3–5)  <0.001
Modified HAS-BLED score†, 
median (IQR)
 2 (2–3)  2 (2–3)  2 (2–3)  0.29
Number of concomitant 
medications, mean (SD)
 3.1 (1.6)  2.9 (1.6)  3.4 (1.6)  <0.001
AF, Atrial fibrillation; CHF, congestive heart failure; CSHA-CFS, Canadian Study of Health and Aging Clinical Frailty Scale; 
IQR, interquartile range; SD, standard deviation; TIA, transient ischemic attack.
*According to the International Society on Thrombosis and Haemostasis definition of major bleeding: fatal bleeding, and/or 
symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or 
pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in hemoglobin level of 2 g/dL or more 
or leading to transfusion of two or more units of whole blood or red cells.
†Labile international normalized ratio was not used in calculating the HAS-BLED score.
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CI 1.09–1.17, P < 0.001) were also significantly 
associated with frailty status (Table 2).
Relationship between Frailty and OAC 
Therapy
Among the 463 patients with a CHA
2
DS
2
-VASc 
score of 2 or greater, there was no significant dif-
ference in the proportion receiving anticoagulant 
therapy between the frail group and the nonfrail 
group (38.2 vs. 42.2%, P = 0.38). In the frail group, 
warfarin was used in 29.3% of the patients and 
non-vitamin K antagonist OACs (dabigatran and 
rivaroxaban) were used in 8.9% of the patients. In 
the nonfrail group, the corresponding proportions 
were 33.2 and 9.0%. Never having been prescribed 
anticoagulants in frail patients (81.7%), rather than 
withdrawal of therapy (18.3%), was more likely to 
be the reason why frail patients were not treated 
with an anticoagulant.
Discussion
Our principal findings in this analysis are as fol-
lows: (1) the prevalence of frailty was about 40% 
65–69
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Figure 2 Prevalence of Frailty According to (A) Age, (B) Sex, and (C) CHA
2
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2
-VASc Score.
Table 2 Multivariable Logistic Analysis of Factors Associated with Frailty Status in Elderly Adult Patients with Atrial Fibrillation.
 OR  95% CI  P-value
Age  1.13  1.09–1.17  <0.001
Female  2.09  1.27–3.43  0.004
CHF  2.40  1.39–4.14  0.002
Hypertension  0.66  0.41–1.05  0.08
Diabetes  1.09  0.70–1.71  0.70
Stroke/TIA  1.29  0.78–2.13  0.32
Coronary heart disease  0.91  0.59–1.42  0.69
Hyperlipidemia  1.02  0.68–1.55  0.92
Major bleeding*  2.22  0.93–5.32  0.07
Chronic liver disease  3.25  0.72–14.6  0.13
Chronic kidney disease  2.12  0.49–9.29  0.32
Previous or current smoking and drinking  1.36  0.79–2.35  0.26
Type of atrial fibrillation  1.31  0.85–2.02  0.23
History of catheter ablation procedure  0.97  0.55–1.74  0.93
Factors included in multivariate logistic regression analysis are all listed.
CHF, Congestive heart failure; CI, confidence index; OR, odds ratio; TIA, transient ischemic attack.
*According to the International Society on Thrombosis and Haemostasis definition of major bleeding: fatal bleeding, and/or 
symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or 
pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in hemoglobin level of 2 g/dL or more 
or leading to transfusion of two or more units of whole blood or red cells.
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among AF patients with a mean age of 75 years; 
(2) advanced age, female sex, and a history of heart 
failure were associated with frailty; (3) the rate of 
use of an anticoagulant was about 40% in this popu-
lation. Lacking OAC prescription was the main rea-
son for no OAC treatment in frail patients.
Prevalence of Frailty in AF Patients and 
Factors Associated with Frailty
The present study shows that frailty was much more 
prevalent among AF patients compared with other 
common diseases and would therefore have a great 
impact on patients’ daily lives. For example, a sys-
tematic review including 21 community-based stud-
ies showed that the prevalence of frailty was 15.7% 
for participants aged 80–84 years and 26.1% for 
participants aged 85 years or older [25]. Compared 
with other chronic diseases, such as type 2 diabe-
tes, frailty status was at least twofold more com-
mon in AF patients. Although our study included 
younger participants, the prevalence of frailty sta-
tus was 40%, compared with 15% in Chinese dia-
betic patients aged between 74 and 84 years [26]. 
A systematic review and meta-analysis found the 
weighted mean prevalence of frailty in patients with 
AF was 39% (95% CI 36–42%), similar to findings 
in the present study [27].
We also found that CHF was associated with a 
2.4-fold higher risk of being frail in elderly adults 
with AF. Coexisting AF and CHF may make patients 
more likely to suffer from cognitive impairment, 
slowing gait speed, and disability [28]. Moreover, 
comorbid AF and CHF leads to worse prognosis 
compared with each condition individually [29, 
30]. Therefore, this group of AF patients should 
optimize their routine heart failure treatment, get 
proper anticoagulant therapy, and may even con-
sider ablation therapy to improve outcomes and 
quality of life [31].
Frailty Status and OAC Therapy
Published data are inconsistent as to whether frailty has 
any impact on anticoagulant therapy use even though 
this has been widely studied [32, 33]. Because of the 
complex impact of frailty on multiple systems, opti-
mizing anticoagulant therapy for frail patients with AF 
is presently challenging. We found that nonprescribing 
rather than withdrawal of therapy was the main rea-
son for lack of OAC treatment in frail patients. Frail 
patients concomitantly used more medications in our 
study, which may negatively affect providers’ prescrip-
tion of OAC. Prior studies demonstrated that provid-
ers had major concerns as to the potential side effects 
of bleeding when prescribing anticoagulants [34, 35]. 
Nevertheless, many studies have found that the prob-
ability of major bleeding in elderly patients receiving 
anticoagulant therapy was not higher than in the over-
all population [36–38]. One study found the net clini-
cal benefits of treating patients with OACs increased 
monotonically with age [39]. A greater understand-
ing of the implications of frailty for the net benefit of 
anticoagulation will be important for health care pro-
viders to facilitate holistic clinical decision-making. 
Discontinuation was another reason for undertreatment 
with OACs in frail elderly patients. Our data suggested 
about 20% of frail patients had ever been treated with 
OACs but the OACs treatment was later discontinued. 
One other study reported that at follow up at 4 years, 
53 of 73 frail elderly patients (72.6%) had discontin-
ued OAC therapy [40]. Optimizing follow-up actions 
for frail AF patients receiving anticoagulant therapy, 
patient education, and consideration of patient values 
may help to minimize the side effects of anticoagulant 
therapy [41, 42].
Limitations
There are several limitations in this study. First, 
most participants were from Beijing, so the con-
clusions may not be generalizable to a broader 
population. As a cross-sectional study, there were 
no follow-up data demonstrating the relationship 
between frailty, anticoagulation, and adverse out-
comes. Finally, this study used a single method 
(CSHA-CFS) to assess the frailty status, mainly 
based on the evaluation of dysfunction, and could 
not fully reflect the decline of physiological func-
tion, which may limit the accuracy of distinguish-
ing nonfrail elderly patients from disabled patients 
[43].
Conclusions
A high proportion (approximately 40%) of patients 
aged 65 years or older with AF were frail, with a 
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history of CHF, female sex, and advanced age being 
associated with frailty status. Nonprescribing was the 
main reason for lack of OAC treatment in frail patients.
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